Amy Stewart, NP, the results of a post-hoc analysis of data from the LIBERTY study in Crohn's disease for Zymfentra, a subcutaneous formulation of infliximab, and how it and other subcutaneous options provide important options for patients...
Amy Stewart, NP, the results of a post-hoc analysis of data from the LIBERTY study in Crohn's disease for Zymfentra, a subcutaneous formulation of infliximab, and how it and other subcutaneous options provide important options for patients...
Amy Stewart, NP, the results of...